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Summary A total of 98 breast aspirates from patients with breast cancer have been fixed and stained for
oestrogen receptors using the Abbott ERICA kit. In a preliminary series of 41 aspirates, cytochemical staining
index (% cells staining x mean intensity) related to the receptor concentration determined biochemically on a
subsequent biopsy with a correlation coefficient of +0.65. In a second series of 56 aspirates examined after
lysis and cytocentrifugation, the correlation coefficient was +0.73. For 14 patients, the response of the
primary tumour to endocrine therapy was assessed objectively by serial clinical and mammographic
measurements (Forrest et al., 1986) and was found to relate strongly to the cytochemical staining of the initial
aspirate. The potential and limitations of this technique are discussed.
The presence of oestrogen receptors within a breast tumour
is now established as an index of both improved prognosis
and increased likelihood of response to endocrine therapy
(Hawkins, 1985). The generation of monoclonal antibodies
against the human oestrogen receptor (Greene et al., 1980)
has permitted the development of commercial kits for both
biochemical (ER-EIA) and histochemical (ER-ICA) assays
by Abbott Laboratories. The results of the latter technique
have been shown to correlate well with those of established
biochemical, steroid-binding (DCC) methods on biopsies of
solid tumour (King et al., 1985; McLelland & Coombes,
1985; McCarty et al., 1985; Hawkins et al., 1986) and the
technique has recently been extended to the assessment of
receptor status in breast cancer cells collected by needle
aspiration (McLelland & Coombes, 1985; Flowers et al.,
1985; McLelland et al., 1987; Cavailles et al., 1987; Wein-
traub et al., 1987). We set out to examine the feasibility of
using such a method and to compare the results of the
technique with (a) those of our standard DCC assay on solid
biopsy, established 15 years ago and (b) response to endo-
crine therapy in patients with large primary tumours.
Methods and materials
Patients
Aspirates were taken from patients presenting to the depart-
mental clinic for the first time. The patients' ages ranged from
33 to 76 years. Aspirates were obtained by making approxi-
mately 10 passes through the tumour using a 21 gauge
needle, mainly by two of us (PAL, EDCA). After preparation
of smears for diagnostic cytopathology, residual material was
used for fixation and cytochemical staining. In one subset of
14 patients with large tumours (>4cm, T2/T3 and one T4),
the patient proceeded after aspiration to wedge biopsy for
further biochemical and histological investigations prior to
initiating endocrine therapy. The response of the primary
tumour was monitored objectively by sequential clinical and
mammographic measurements (Forrest et al., 1986). Of these
patients, five received the LHRH agonist Zoladex (ICI
118630), five aminoglutethimide, two 4-hydroxyandrostened-
ione and two tamoxifen. One patient was premenopausal, 12
were postmenopausal and one was male. Response was
classed as regression, progression or stasis depending on a
statistical evaluation of the changes in tumour size during a
12-week period (see Forrest et al., 1986). The biochemical
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value of oestrogen receptor concentration was recorded in
the patient's notes at the start of treatment but 'response'
was decided by statistical evaluation, and in the absence of
the knowledge of the cytochemical assay result.
Cytochemical assay
In an initial series of 41 patients, aspirates were taken and
fixed by a variety of techniques (A, B, C, D): in brief, these
involved:
A. Preparation of a smear and fixation immediately in the
clinic;
B. Preparation of a smear, storage on dry ice and fixation
at the end of the clinic (essentially the method of
Coombes et al., 1987);
C. Collection of the aspirate in 'storage buffer' (PBS
containing 50% glycerol v/v and 3 mM magnesium
chloride), on ice, with cytocentrifugation and fixation at
the end of the clinic;
and
D. Collection of the aspirate in saline/tissue culture medium
(RPMI), on ice, with cytocentrifugation and fixation at
the end of the clinic.
Ultimately a fifth method (E) was preferred and this was
used to process a second series of aspirates from a further 56
patients. In this method (which is essentially that employed
by Dr R.E. Leake, Department of Biochemistry, University
of Glasgow), the residue of aspirate remaining after the
preparation of the diagnostic smears was flushed gently from
the syringe using tissue culture medium (0.2-1.0ml RPMI).
After addition of water (3:2 v/v) and brief (30sec), gentle
agitation to lyse red cells, further RPMI (12:5 v/v) was
added and the cells were harvested by centrifugation for
15 min at 230g in an MSE Mistral centrifuge. After removal
of the supernatant fluid, the cells were resuspended in a
suitable volume of medium (.300,ul) and three 100,ul
aliquots were cytospun for 10min at 1,000rpm (89g) onto
slides precoated with polylysine (Abbott) in a Cytospin 2
centrifuge. In order to ensure adhesion of the cells to the
slides, these were left to air-dry for 2min, prior to fixation
and staining with the Abbott ERICA kit as we have
described previously (Hawkins et al., 1986). A single quality
control slide (Abbott) was stained in each batch of aspirates.
Each slide was assessed independently by two observers
(RAH, KS) for (a) the % cells staining, and (b) an average
intensity of staining on a scale of 0, 1, 2 or 3 for all the cells
in the cytospun area. After correction for any staining in the
'control' section (exposed to non-specific rat serum), a
cytochemical staining index (average intensity of staining
Br. J. Cancer (1988), 58, 77-8078 R.A. HAWKINS et al.
x % cells staining/I00) was calculated for the 'test' section
(exposed to the anti-receptor antibody). Where there was
significant disagreement between the observers (11.8%
cases), the slides were accepted after rescoring by mutual
consent (7.5%) or rejected as 'unassessable' (4.3%). Speci-
mens showing very few cells, very large amounts of non-
specific (control) staining or for which the formal histopatho-
logical report was 'benign' or 'inadequate' were also rejected.
Specimens from patients on tamoxifen at aspiration were
excluded.
In the second series of aspirates, for example, the 56
assessable specimens were derived from a total of 91
patients, exclusions being 3 because of tamoxifen treatment,
15 unassessable and 17 because the formal diagnostic smear
was classified as 'acellular', 'benign' or 'lymphoma'.
Biochemical assay of oestrogen receptor activity
Solid tumour was obtained by biopsy or mastectomy, within
1-2 weeks of aspiration. This was used for the determination
of oestrogen receptor activity by saturation analysis, with
separation of free and bound hormone by dextran-coated
charcoal (DCC) adsorption as described previously (Hawkins
et al., 1981). Specimens containing _5 fmol oestrogen recep-
tor sites mg-1 soluble protein are considered
'receptor-positive'.
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Figure 1 Relationship between cytochemical staining (ERICA)
of an aspirate and oestrogen receptor concentration determined
by DCC assay in a subsequent biopsy for 56 patients with breast
cancer. Staining index = average staining intensity x % cells stain-
ing/100 and is the mean of observations by two observers. The
correlation coefficient (Spearman Rank Test) was +0.73.
Results
1. Correlation between cytochemical and biochemical
estimates of receptor activity
In a preliminary series of 41 patients (of average age 55
years), 78% of the tumours contained receptors (range 5-
789fmolmg-1 protein) by DCC assay and 73% showed
cytochemical staining after fixation by a variety of methods
(A, B, C, D). The degree of cytochemical staining ('staining
index') in the tumour aspirate ranged from 0 to 2.9 and
correlated moderately well (r= +0.65) with the receptor site
concentration determined biochemically by DCC assay on
the subsequent surgical biopsy specimen (not shown). In this
series, however, cell losses during fixation and processing
were a problem. A second series was therefore examined by
method 'E'.
In the second series of patients (of average age 61 years),
48/56 (86%) of the tumours contained receptors (5-
933 fmolmg-1 protein) by DCC assay and 46/56 (82%)
showed staining. The degree of staining in these cells,
ranging from 0 to 2.9, showed a slightly stronger correlation
with receptor site concentration by DCC assay (r= +0.73);
the data are plotted in Figure 1. Similar correlations were
observed when the relationship between % cells staining
(r= +0.69) or staining intensity (r= +0.78) and receptor
concentration were examined separately (not shown). It is
noted, however, that under the conditions of assay
employed, the tissues of receptor concentration less than
30 fmol mg 1 protein showed relatively low levels of staining.
The relationship between the qualitative categorisations of
each assay result is summarised in Table I.
2. Relationship of cytochemical staining for receptor and
response to endocrine therapy
Response of the primary tumour to endocrine therapy was
assessed in 14 patients with large, but operable primary
tumours. Six of the patients responded, 5 showed no clear
change on therapy and 3 tumour progression (Table II).
With one exception, the tumours showing regression had a
staining index of > 1.40; tumours showing stasis had indices
between 0.12 and 1.05, and those tumours which progressed
an index of 0.
Again in this small subseries, cytochemical staining corre-
lated strongly with biochemical receptor site concentration
(r= +0.93). Accordingly, biochemical receptor site concen-
Table I The qualitative relationship between cytochemical
staining (ERICA) on an aspirate and oestrogen receptor
activity determined biochemically by DCC assay in 56
patients with breast cancer
Biochemical receptor activitya Cytochemical stainingb
(fmolmg'-'protein) (-) (+)
7 1
+ 3 45
r2 with Yates' correction=25.57
P<0.0005
aActivity was taken as - when receptor site concentration
was <5 fmolmg-1 protein and + when >5; bStaining was
taken as - when the staining index=0 and all values >0
were designated '+'.
Table II Relationship between cytochemical staining (ERICA) in
breast tumur aspirates and response to endocrine therapy
Biochemical
Cytochemical fmol receptor sites
staining indexb mgI protein Clinical
Patient (aspirates) (biopsy) response
1 2.90 174 Regra
2 2.25 364 Regr
3 2.25 344 Regr
4 1.83 412 Regr
5 1.40 147 Regr
6 1.05 167 Stasis
7c 0.55 91 Stasis
8 0.51 73 Stasis
9 0.49 n.a. Stasis
10 0.12 77 Stasis
11 0.03 17 Regr
12 0 6 Progression
13 0 0 Progression
14 (male) 0 0 Progression
aRegr =regression; bStaining index staining intensity x % cells
staining/100; cEarly T4 tumour, all other patients had T2/T3
tumours; n.a.=no biopsy available.
tration and cytochemical staining index both appeared to
relate equally well to clinical response.
The same data are shown expressed in qualitative terms in
the contingency Table III, where it can be seen that there is
a significant relationship between receptor status and res-
ponse for the cytochemical assay, though the relationship for
the biochemical assay does not quite attain significance.
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Table III Relationship between receptor status and
response to endocrine therapy in 14 patients with large,
primary tumours of the breast
Receptor status Regression Stasis Progression
Cytochemical staininga
+ 6 5 0
0 0 3
Biochemical receptor activityb P<0.0055
+ 6 5 1
0 0 2
P<0.066
aStaining was taken as - when the staining index =0
and all values >0 were designated '+'; bActivity was
taken as - when receptor site concentration was
<5fmolmg-' protein and + when _5; P values were
derived from an exact test for trend.
Discssion
The studies which we report here confirm the reports of
others who have suggested that cytochemical staining of
breast aspirates by the ERICA kit (1) accurately reflects the
oestrogen receptor content of the tumour and therefore (2)
accurately relates to the patient's clinical response to endo-
crine therapy. Despite the presence of a few tumours of
moderate/higher receptor value showing a low staining index
(<0.5, see Figure 1), there was a good correlation between
cytochemical and biochemical assays. The reasons for the
low degree of staining in a few tumours of higher biochemic-
ally determined receptor concentration are not fully resolved.
Inspection of such specimens shows that the lower values of
staining index derive almost entirely from the small percent-
age of the cells showing staining and not from a low
intensity of staining. However, these specimens were not
associated with either poorer cellularity or higher blood
content than those showing a stronger correlation between
cytochemistry and biochemistry. Nevertheless our finding of
a correlation coefficient of +0.73 (n = 56) for the quantitative
relationship between staining on aspirates and receptor site
concentration in a biopsy agrees well with the equivalent
correlations of +0.74 (n=33) and +0.76 (n=35) reported by
Flowers et al. (1985) and Cavailles et al. (1987) respectively.
These correlations are higher than that of +0.48 (n =95)
found by McLelland et al. (1987), but their series included
some comparisons between ERICA staining and DCC assays
on different tumour deposits. Weintraub and his colleagues
(1987) compared ERICA staining in aspirates and frozen
sections from the same tumour specimen and also found a
correlation coefficient of +0.72 (n=31); however, there was a
lesser correlation (+0.55) between aspirate staining and the
concentration of biochemically determined receptor sites. In
general, these correlations are of the same order of magni-
tude as those found by ourselves (r= +0.87, n =34, Hawkins
et al., 1986) and others, e.g. Andersen et al. (1986)
(r= +0.91, n=35), McCarty et al. (1985) (r= +0.79, n=62)
and King et al. (1985) (r=+0.76, n=38) when comparing
ERICA staining in frozen or paraffin sections with the
concentration of biochemically determined receptor sites in
the same tumour specimen. In view of the heterogeneity of
breast tumours with respect to oestrogen receptor concent-
ration (e.g. Braunsberg et al., 1975; Hawkins et al., 1977;
Senbanjo et al., 1986), it may not be possible to attain a
better correlation between assays on aspirates and those on
excision biopsies.
The relationship between ERICA staining and response to
endocrine therapy has been determined on only a small series
of patients. Nevertheless, in our experience, the primary
tumour model used gives a much more precise index of
tumour response than do studies of metastatic disease: it
allows receptor activity and response of the same tumour
mass to be related. The relationship between staining and
response is striking and could not occur by chance. These
findings support the contention of Coombes et al. (1987)
who, though using a slightly different technique for process-
ing of the aspirates, demonstrated that cytochemical staining
accurately predicts response to endocrine therapy in 60
patients with metastatic or locally advanced breast cancer.
The present data are insufficient to allow selection of a
clinically useful 'cut-off point' for the staining index, though
McLelland & Coombes (1985) have previously suggested a
value of 0.5 on a comparable scale.
It is to be noted that for one patient (Number 11),
response was associated with a very low staining intensity:
this woman was postmenopausal, treated by administration
of LHRH agonist and showed a statistically significant
regression. Pretreatment receptor levels were low by either
cytochemical or biochemical techniques, though at subse-
quent mastectomy, a second biochemical assay showed a
much higher receptor level (102 fmolmg-1 protein).
Despite the potential value of the staining of breast
aspirates by ERICA, it is important to consider five limi-
tations to this method. Firstly, the method we have preferred
does produce some morphological damage to the aspirated
cells and would not permit interpretation of cell-type in all
cases, though a concomitant smear, fixed directly, can easily
be processed for each aspirate. Reduction of the centrifuga-
tion times and g forces to 5 min at 115g for harvesting the
cells and 4min at 89g for cytospinning has been found
subsequently to lessen the damage. This technique differs
from the more direct method of preparing a smear used by
Coombes and his group. In our hands, however, we found
that staining smears used much larger amounts of antibody,
yielded much wider areas to assess microscopically, and gave
problems, with the interpretation particularly of bloody
smears, since red blood cells contain high levels of endogen-
ous peroxidase. Secondly, in its present form, the assay may
not be sufficiently sensitive to detect staining in some
premenopausal women who, with low levels of receptor
activity by biochemical assay (20-30 fmolmg- I protein) may
nevertheless respond to endocrine therapy (Hawkins -
unpublished, Nicholson, R.I. - personal communication).
Thirdly, a minimum number of tumour cells (perhaps 20) is
required as an adequate sample for assessment: although
staining may be visible in a lesser number of cells, the small
number of cells may be insufficient to take account of
possible heterogeneity (R+ and R- cells). We would not
agree with Flowers et al. (1985), who considered 5 cells as
adequate. Fourthly, it is important that some measure of
quality control be applied to the ERICA assays to ensure
consistent sensitivity. Although we routinely processed and
scored the control slide provided by Abbott, this single
control may be inappropriately high for assessing samples
with receptor levels as low as 20fmolmg-1 protein and we
did detect some significant variations in staining of the
control slide between assays. This may be of importance
since our experience with advanced disease would indicate
that 20 fmolmg-1 protein is a suitable 'cut-off' for selecting
patients for endocrine therapy. Lastly, since neither of us
who scored the slides were pathologists, we confined our
assessments to only those patients in whom carcinoma had
been diagnosed by the breast cytologist on concomitantly
prepared smears of the aspirated cells, and it may well be
that a superior predictive index can be derived when the
stained material is scored by an experienced breast
cytopathologist.
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